Slide 1: From PhD Project to Billion Dollar Deal
From PhD Project to Billion Dollar Deal Per Norlén, CEO Strictly private and confidential 7th December 2016
Slide 2: Alligator develops agonistic antibodies for tumor directed immunotherapy
Alligator develops agonistic antibodies for tumor directed immunotherapy 2015 ADC-1013 entering clinical phase I & major out-licensing deal 2013 ALLIGATOR-GOLD® antibody library 2012 Focus extended to bispecific antibodies 2008 Strategic focus on immuno-oncology 2001 FIND® and foundation of Alligato
Slide 3: Rapid development within the field of immuno-oncology
Rapid development within the field of immuno-oncology Sales of existing immuno-oncology treatments Projected immuno-oncology market development US$ Million US$ Billion 2 634 30 566 21.5% 1 369 942 35.8% 960 706 360 1 126 42.8% 3 2011 2012 2013 2014 2015 2015 2023E Yervoy® Opdivo® Keytruda® Treatment
Slide 4: Immuno-oncology – using the immune system to kill cancer
Immuno-oncology – using the immune system to kill cancer Metastases Dendritic cell T-cell Tumor Cancer immunotherapy switches the balance from immunosuppression to immune activation, resulting in immune-mediated tumor eradication 4
Slide 5: Tumor-directed immunotherapy
Tumor-directed immunotherapy Metastases Immune activation Tumor S Y S T E M I C I M M U N O - A C T I V AT I O N T U M O R - D I R E C T E D I M M U N O - A C T I V AT I O N General immune activation with severe toxicity Tumor-selective immune activation with less toxicity 5
Slide 6: Alligator drug development pipeline
Alligator drug development pipeline RESEARCH PRE-CLINICAL DEVELOPMENT PHASE I PHASE II ADC-1013* (CD40) ATOR-1015 (OX40/CTLA-4) ATOR-1016 (TNFR-SF/TAA) (TNFR-SF) (TNFR-SF/ND) TNFR-SF: Tumor Necrosis Factor Receptor-Superfamily TAA: Tumor-Associated Antigen ND: Not Disclosed *Partnered with Janssen B
Slide 7: ADC-1013 – First experiment in 1999
ADC-1013 – First experiment in 1999 B44 lab book notes, page 58, 1999 Nov 11
Slide 8: Lead Optimization of CD40 Antibody
Lead Optimization of CD40 Antibody Affinity maturation using FIND®. Affinity improved from 1 to 0.01 nM. Increased tumor retention through elevation of isoelectric point Affinity/Off-rate ADC-1013 B44 Binding maximum
Slide 9: CD40 is a key immuno-oncology target
CD40 is a key immuno-oncology target Mode of Action Co-stimulating receptors ANTIGEN-PRESENTING CELL T CELL ANTIGEN-PRESENTING CELL T CELL PDL1 or PDL2 ? + ADC-1013 PDL1 or PDL2 PD1 – CD40 CD80 or CD86 CD28 + CD80 or CD86 CTLA4 – B7RP1 ICOS + B7-H3 ? – B7-H4 ? – T-cell Dendritic HVEM BTLA – cell Pep
Slide 10: ADC-1013 clinical trial
ADC-1013 clinical trial 40 patients with solid tumors 5 clinical sites in UK, DK and SE Dosing & Primary Secondary administration endpoint endpoints FiH, first dose April 2015 Safety and tolerability PK & PD Dose escalation Immunogenicity Intra-tumoral & intravenous Clinical efficacy Sou
Slide 11: Partnership with Janssen
Partnership with Janssen Description of agreement Royalty / Milestone potential Exclusive world-wide license Up-front payment plus additional milestones of up to US$ 700 million Alligator continues as sponsor for the ongoing Phase I clinical trial Tiered high single digit to low double digit
Slide 12: ADC-1013 out-licensing – success factors
ADC-1013 out-licensing – success factors Strong scientific rationale, internal expertise and scientific collaborations Well positioned: potential for first in class and best in class Extensive pre-clinical data package Data package included all data likely to be requested, including strong b
Slide 13: Thank You!
Thank You! Strictly private and confidential